Cargando…
Intratumoural Treatment of 18 Cytologically Diagnosed Canine High-Grade Mast Cell Tumours With Tigilanol Tiglate
Canine high-grade mast cell tumours (HGMCT) are associated with a poor prognosis, are inherently more invasive, and have higher rates of local recurrence. The primary aim of this retrospective study was to assess the efficacy of intratumoural tigilanol tiglate (TT) as a local treatment option. Eight...
Autores principales: | Brown, Graham K., Campbell, Justine E., Jones, Pamela D., De Ridder, Thomas R., Reddell, Paul, Johannes, Chad M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429927/ https://www.ncbi.nlm.nih.gov/pubmed/34513966 http://dx.doi.org/10.3389/fvets.2021.675804 |
Ejemplares similares
-
Treatment of multiple synchronous canine mast cell tumours using intratumoural tigilanol tiglate
por: Brown, Graham K., et al.
Publicado: (2022) -
Use of the Intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses
por: De Ridder, Thomas, et al.
Publicado: (2020) -
Tigilanol Tiglate-Mediated Margins: A Comparison With Surgical Margins in Successful Treatment of Canine Mast Cell Tumours
por: De Ridder, Thomas, et al.
Publicado: (2021) -
Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors
por: Miller, Jane, et al.
Publicado: (2019) -
Wound formation, wound size, and progression of wound healing after intratumoral treatment of mast cell tumors in dogs with tigilanol tiglate
por: Reddell, Paul, et al.
Publicado: (2021)